| 摘要 |
A series of novel spiro-oxindole oxazolidinedione derivatives have been prepared, including their base salts with pharmacologically acceptable cations. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Preferred compounds include 1-(p-fluorophenyl)-5-fluoro-spiro-[indoline-3,5 min -oxazolidine]-2,2 min ,4 min -trione, 1-methyl-5-chloro-spiro-[indoline-3,5 min -oxazolidine]-2,2 min ,4 min -trione, 1-isopropyl-5-chloro-spiro-[indoline-3,5 min -oxazolidine]-2,2 min ,4 min -trione and 1-(P-chlorobenzyl)-5-chloro-spiro-[indoline-3,5 min -oxazolidine]-2,2 min -4 min -trione. Methods for preparing these compounds from known starting materials are provided. |
